Literature DB >> 2076727

An examination of a possible pharmacokinetic interaction between nifedipine and antipyrine.

T Edeki1, A Johnston, P Turner.   

Abstract

The influence of 2 weeks oral intake of nifedipine (2 x 20 mg) on the oxidative metabolism of antipyrine was investigated in 12 normal volunteers, who had 1050 mg antipyrine solution orally before and after the course of nifedipine. There were no statistically significant differences in the saliva pharmacokinetic parameters of antipyrine on both occassions. However, the metabolite profile of antipyrine in urine showed a significant reduction in the amount of norantipyrine excreted after compared to that before nifedipine administration (16.5 vs 19.6%). This may have implications for drugs that share a similar demethylation pathway with norantipyrine.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2076727     DOI: 10.1007/BF00315420

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  22 in total

1.  Calcium channel antagonists: pharmacological considerations.

Authors:  D Rampe; C M Su; F Yousif; D J Triggle
Journal:  Br J Clin Pharmacol       Date:  1985       Impact factor: 4.335

2.  Effect of oral administration of a new calcium channel blocking agent, bepridil on antipyrine clearance in man.

Authors:  C Funck-Brentano; P L Chaffin; G R Wilkinson; B McAllister; R L Woosley
Journal:  Br J Clin Pharmacol       Date:  1987-10       Impact factor: 4.335

3.  Further observations on relationships between antipyrine half-life, clearance and volume of distribution: an appraisal of alternative kinetic parameters used to assess the elimination of antipyrine.

Authors:  L G Sultatos; B H Dvorchik; E S Vesell; D G Shand; R A Branch
Journal:  Clin Pharmacokinet       Date:  1980 May-Jun       Impact factor: 6.447

4.  Inhibition of hepatic microsomal drug metabolism by the calcium channel blockers diltiazem and verapamil.

Authors:  K W Renton
Journal:  Biochem Pharmacol       Date:  1985-07-15       Impact factor: 5.858

5.  Diltiazem treatment impairs hepatic drug oxidation: studies of antipyrine.

Authors:  G Carrum; J M Egan; D R Abernethy
Journal:  Clin Pharmacol Ther       Date:  1986-08       Impact factor: 6.875

6.  Theophylline metabolism in relation to antipyrine, debrisoquine, and sparteine metabolism.

Authors:  R Dahlqvist; L Bertilsson; D J Birkett; M Eichelbaum; J Säwe; F Sjöqvist
Journal:  Clin Pharmacol Ther       Date:  1984-06       Impact factor: 6.875

7.  Pharmacokinetics and metabolism of nifedipine.

Authors:  K D Raemsch; J Sommer
Journal:  Hypertension       Date:  1983 Jul-Aug       Impact factor: 10.190

8.  Comparison of the in vivo and in vitro rates of formation of the three main oxidative metabolites of antipyrine in man.

Authors:  A R Boobis; M J Brodie; G C Kahn; E L Toverud; I A Blair; S Murray; D S Davies
Journal:  Br J Clin Pharmacol       Date:  1981-12       Impact factor: 4.335

9.  Pharmacokinetic studies of nifedipine tablet. Correlation with antihypertensive effects.

Authors:  A M Taburet; E Singlas; J N Colin; O Banzet; M Thibonnier; P Corvol
Journal:  Hypertension       Date:  1983 Jul-Aug       Impact factor: 10.190

10.  Nifedipine in unstable angina: a double-blind, randomized trial.

Authors:  G Gerstenblith; P Ouyang; S C Achuff; B H Bulkley; L C Becker; E D Mellits; K L Baughman; J L Weiss; J T Flaherty; C H Kallman; M Llewellyn; M L Weisfeldt
Journal:  N Engl J Med       Date:  1982-04-15       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.